Strategic Partners Competitors and Similar CompaniesClear all

Strategic Partners's competitors and similar companies include Pharming Group, Ionis Pharmaceuticals, Lexicon Pharmaceuticals and CRISPR Therapeutics.

	Strategic Partners Strategic Partners (formerly known as Orphazyme) is a company that forms partnerships with biotech, industrial, commercial, property, and asset management companies.	Pharming Group Pharming Group is a biopharmaceutical company developing protein replacement therapies and precision medicines for the treatment of rare diseases.	Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.	Lexicon Pharmaceuticals Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology.	CRISPR Therapeutics CRISPR Therapeutics is a gene editing company focused on developing transformative gene-based medicines for the treatment of serious human diseases.
Founding Date	Founding Date 2009	Founding Date 1988	Founding Date 1989	Founding Date 1995	Founding Date 2013
Type	Type Public	Type Public	Type Public	Type Public	Type Public
Tags	Tags Financial Services financial management	Tags Healthcare biotech pharma therapy	Tags Healthcare biotech drug development genetics pharma	Tags Healthcare biotech drug development genetics pharma	Tags Healthcare biotech drug development genetics pharma
Locations	Locations København, DK HQ Chicago, US Newton, US	Locations Leiden, NL HQ Leiden, NL	Locations Carlsbad, US HQ Vancouver, CA Stuttgart, DE Dublin, IE Dublin, IE Lisboa, PT London, GB see more	Locations The Woodlands, US HQ Jersey, JE Atlanta, US Bernards, US Birmingham, US Boston, US Charlotte, US see more	Locations Zug, CH HQ Greater London, GB Cambridge, US San Francisco, US
Employees	Employees 1	Employees 404	Employees 1,40231% increase	Employees 20216% increase	Employees 393
Valuation ($)	Valuation ($) 6.8 m	Valuation ($) 590.3 m	Valuation ($) 6.3 b	Valuation ($) 737.4 m	Valuation ($) 4.2 b
Financial
Revenue (est.)	Revenue (est.) kr309k (FY, 2025)	Revenue (est.) $376.1m (FY, 2025)	Revenue (est.) $943.7m (FY, 2025)	Revenue (est.) $49.8m (FY, 2025)	Revenue (est.) $3.5m (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods $41.6m (FY, 2025)	Cost of goods $15.9m (FY, 2025)	Cost of goods $274k (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit kr309k (FY, 2025)	Gross profit $341m (FY, 2025)	Gross profit $927.8m (FY, 2025)	Gross profit $49.5m (FY, 2025)	Gross profit N/A
Net income	Net income (kr859k) (FY, 2025)	Net income $2.5m (FY, 2025)	Net income ($381.4m) (FY, 2025)	Net income ($50.3m) (FY, 2025)	Net income ($581.6m) (FY, 2025)
Operating ⚠
Phase I Trials Products	Phase I Trials Products N/A	Phase I Trials Products 2 (Q3, 2020)	Phase I Trials Products 1 (FY, 2023)	Phase I Trials Products 1 (FY, 2016)	Phase I Trials Products N/A
Phase II Trials Products	Phase II Trials Products N/A	Phase II Trials Products 1 (Q3, 2020)	Phase II Trials Products 18 (FY, 2024)	Phase II Trials Products N/A	Phase II Trials Products N/A
Phase III Trials Products	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products 17 (FY, 2024)	Phase III Trials Products 2 (FY, 2016)	Phase III Trials Products N/A
Funding
Total funding raised	Total funding raised $ 58.8m	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 244.7m	Total funding raised $ 127m